Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials for cytoprotection in stroke.

Lise A Labiche1, James C Grotta

  • 1Stroke Program, University of Texas at Houston Medical School, 6431 Fannin Street, Houston, Texas 77030, USA.

Neurorx : the Journal of the American Society for Experimental Neurotherapeutics
|February 18, 2005
PubMed
Summary

Many neuroprotective drugs fail in acute stroke trials despite promising preclinical data. Improved trial designs and multimodal therapies are being explored to enhance efficacy and optimize tissue salvage in stroke patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular Neurology Fellowship: Where Do We Go From Here?

Stroke·2026
Same author

Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication.

Lancet (London, England)·2026
Same author

Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.

Stroke·2026
Same author

CREST-2: Providing Clarity on Managing Asymptomatic Carotid Stenosis.

Stroke (Hoboken, N.J.)·2026
Same author

Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

General Anesthesia Versus Conscious Sedation for Mechanical Thrombectomy in Patients With Acute Ischemic Stroke in the MOST Trial.

Journal of the American Heart Association·2026

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Pharmacology

Background:

  • Numerous cytoprotective drugs have undergone Phase 3 trials for acute stroke.
  • A consistent theme in neuroprotection research is the failure to demonstrate efficacy in clinical trials, contrasting with positive preclinical findings.

Purpose of the Study:

  • To review individual therapeutic strategies in neuroprotection for acute stroke.
  • To highlight lessons learned from clinical trials regarding trial design and the biological effects of neuroprotective agents.

Main Methods:

  • Analysis of existing literature on neuroprotective drug trials in acute stroke.
  • Focus on advancements in trial design, including patient selection, randomization, therapeutic windows, and monitoring.
  • Examination of multimodal therapies and cytoprotection/reperfusion strategies.

Related Experiment Videos

Main Results:

  • Despite rigorous trial designs in recent studies, many neuroprotective agents have shown neutral or negative results.
  • Preclinical studies often yield encouraging outcomes that do not translate to clinical efficacy.
  • Newer trials incorporate stricter criteria, surrogate markers, and combination therapies.

Conclusions:

  • The discrepancy between preclinical promise and clinical failure in neuroprotection for stroke persists.
  • Refined clinical trial methodologies are crucial for accurately assessing neuroprotective agents.
  • Future strategies may involve multimodal approaches and optimized therapeutic interventions for stroke patients.